Coronavirus

The JPEO's COVID-19 Support

Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)'s core focus areas contribute to building a more lethal force, a priority in the National Defense Strategy, and streamline JPEO-CBRND efforts to meet the Joint Service’s needs in combating chemical, biological, radiological and nuclear (CBRN) threats.

JPEO-CBRND is supporting our interagency partners in their response to the COVID-19 pandemic, from helping develop detection, diagnosis, treatment, and vaccines for our Warfighters, to tools that increase situational awareness of the coronavirus, all thanks to our team effort with industry and academia.

The JPEO-CBRND's Support to the National COVID-19 Response 


JPEO's and the Army's support to the COVID-19 response, with our partners, people, products & processes
Since the start of the pandemic, JPEO-CBRND's workforce has worked tirelessly to help procure and deliver COVID-19 medical countermeasures for the nation and the Joint Force. This snapshot captures our efforts in the National COVID-19 Response.

Download Our National COVID-19 Response Infographic

Quick Links

 

COVID-19 Fact Sheets
JPL CBRND Enabling Biotechnologies COVID-19 Surveillance Stick
April 23, 2021 - Download a copy by clicking the image.

JPL CBRN IM/IT Global Biosurveillance Portal(GBSP)
April 23, 2021 - Download a copy by clicking the image.

JPL CBRND Enabling Technologies DNA Vaccine
April 22, 2021 - Download a copy by clicking the image.

JPL CBRN Special Operations Forces Biomeme COVID-19 Test Systems
April 22, 2021 - Download a copy by clicking the image.

JPM CBRN Protection COVID-19 Negatively Pressurized CONEX (NPC), NPC-Lite (NPCL) JUON
April 22, 2021 - Download a copy by clicking the image.

JPM CBRN Medical's Development of Remdesivir: A Broad-Spectrum Antiviral Drug
April 22, 2021 - Download a copy by clicking the image.

JPM CBRN Medical COVID-19 Diagnostic Capability: Cepheid GenExpert
April 22, 2021 - Download a copy by clicking the image.

JPM CBRN Medical COVID-19 Diagnostic Capability: NGDS 1 (BioFire FilmArray)
April 22, 2021 - Download a copy by clicking the image.

Medical Countermeasures Advanced Development and Manufacturing (ADM)
April 9, 2021 - Download a copy by clicking the image.
COVID News
Ellume - JPM CBRN Medical Provides Relief and Recovery in the Age of a Global Pandemic
NEW YORK (May 30, 2020) U.S. Army Pfc. Joshua Jenkins, assigned to the 44th Medical Brigade, conducts a COVID-19 swab test on U.S. Army Staff Sgt. Michael Ciske, at a mobile testing center outside the Javits Center in New York City, May 30, 2020. Military medical personnel assigned to the hospital collaborate as an integrated system in support of New York City medical system, as part of the Department of Defense COVID-19 response. U.S. Northern Command, through U.S. Army North, remains committed to providing flexible Department of Defense support to the Federal Emergency Management Agency for the whole-of-nation COVID-19 response. (U.S. Navy photo by Mass Communication Specialist 1st Class Kleynia R. McKnight)
Oct. 4, 2021 - The JPM CBRN Medical team is dedicated to mission, warfighter, and Nation. Their work has been instrumental in bringing novel testing capability to the U.S., delivering critical at-home technology necessary to combat the...

JPM CBRN Medical Provides Relief and Recovery in the Age of a Global Pandemic
Aerial photo of Ellume's new Fredrick, MD diagnostics manufacturing facility.
Sept. 8, 2021 - What do global pandemic relief efforts, the U.S. Army, and a local Maryland economy have in common? The answer is fearless innovation, the right people in the right place at the right time, and an Australian-based biotech and...

DOD Awards $64.6 Million Contract to SiO2 Medical Products to Increase Domestic Production Capacity of Pharmaceutical Vials
Crystal Tyler, pharmacy technician, prepares an injection for an Operation Warp Speed patient volunteer at Brooke Army Medical Center, Fort Sam Houston, Texas, November 16, 2020. BAMC and Wilford Hall Ambulatory Surgical Center are participating in the Phase III trial to evaluate the vaccine under development by AstraZeneca as part of a national initiative to accelerate the development, production and distribution of COVID-19 vaccines, therapeutics and diagnostics. (U.S. Army photo by Jason W. Edwards)
July 29, 2021 - IMMEDIATE RELEASE - On July 26, 2021, the Department of Defense (DOD), on behalf of and in coordination with the Department of Health and Human Services (HHS), awarded a $64.6 million contract modification to SiO2 Medical...

Biden Administration announces U.S. government procurement of Merck’s investigational antiviral medicine for COVID-19 treatment
American Flags © iStock.com/ranckreporter
June 9, 2021 - The Biden Administration today announced that the U.S. government will procure approximately 1.7 million courses of an investigational antiviral treatment, molnupiravir (MK-4482), for COVID-19 from Merck, pending emergency...

Memorandum of Understanding for Acquisition Support Signed Between the Department of Defense and the Department of Health and Human Services
American Flags © iStock.com/ranckreporter
May 26, 2021 - On May 20, 2021, Deputy Secretary of Defense Kathleen Hicks and Deputy Secretary of Health and Human Services (HHS) Andrea Palm signed a memorandum of understanding (MOU) to continue the agencies’ partnership in defeating...

Interview with Dr. Kevin Wingerd Chief Technology Officer at the Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical)
May 25, 2021 - Excerpt from NCT Magazine's Interview with Dr. Kevin Wingerd, Chief Technology Officer at the Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical)...

The COVID-19 Pandemic: Acquisition of Diagnostic Equipment and Testing Assays for COVID-19 Lays the Groundwork for Vaccine and Treatment Success
NEW YORK (May 30, 2020) U.S. Army Pfc. Joshua Jenkins, assigned to the 44th Medical Brigade, conducts a COVID-19 swab test on U.S. Army Staff Sgt. Michael Ciske, at a mobile testing center outside the Javits Center in New York City, May 30, 2020. Military medical personnel assigned to the hospital collaborate as an integrated system in support of New York City medical system, as part of the Department of Defense COVID-19 response. U.S. Northern Command, through U.S. Army North, remains committed to providing flexible Department of Defense support to the Federal Emergency Management Agency for the whole-of-nation COVID-19 response. (U.S. Navy photo by Mass Communication Specialist 1st Class Kleynia R. McKnight)
May 25, 2021 - In early 2020, the world as we knew it began to change. Lockdowns, mask mandates, and travel bans became the new normal as the world fought to slow the spread of the coronavirus (COVID-19).Priorities began to shift, and the...

DOD & HHS Announce DPA Title III Agreement With Retractable Technologies, Inc. to Expand Domestic Production Capacity for Low Dead-Space Safety Syringes and Needles
Syringes with the Moderna COVID-19 vaccine sit on a table while personnel register to receive the immunization inside the clinic at Camp Arifjan, Kuwait, Jan. 18, 2021. Camp Arifjan is currently in phase one of the Department of Defense’s three-phased approach to administering the vaccine, which prioritizes health care providers, support staff, emergency services and public safety personnel. (U.S. Army photo by Sgt. 1st Class Noel Gerig, 1st TSC Public Affairs)
May 24, 2021 - As part of the national response to COVID-19, the Department of Defense (DOD), in coordination with the Department of Health and Human Services (HHS), signed an agreement with Retractable Technologies, Inc. (RTI) to expand...

Sanofi-GSK report positive interim results for their COVID-19 shot
JACKSONVILLE, Fla. (June 24, 2020) – A hospitalman prepares supplies at Naval Hospital Jacksonville’s “swab tent” during the COVID-19 pandemic.  The hospital’s providers refer patients to this service for screening and test sample collection, when medically indicated.  This service isn’t available for walk-in; a provider referral is needed.  Patients are asked to call ahead (to the 24/7 Nurse Advice Line) for COVID-19 concerns.  Patients can call the appointment line, for a Navy Care virtual visit or in-person care.  NH Jacksonville continues to align its services with community conditions and each installation’s Health Protection Condition.  (U.S. Navy photo by Jacob Sippel, Naval Hospital Jacksonville/Released).
May 17, 2021 - An experimental COVID-19 vaccine developed by Sanofi and GlaxoSmithKline showed a robust immune response in early-stage clinical trial results, enabling them to move to a late-stage study, the French drugmaker said on Monday...

Using Ultrasound Stimulation to Reduce Inflammation in COVID-19 In-Patients
May 12, 2021 - Researchers at University of California San Diego School of Medicine have begun a pilot clinical trial to test the efficacy of using ultrasound to stimulate the spleen and reduce COVID-19-related inflammation, decreasing the...

INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine
WASHINGTON (Dec. 15, 2020) Medical workers who received Pfizer’s COVID-19 vaccine at Washington DC Veterans Affairs Medical Center were also given a sticker commemorating the event. The vaccine was delivered as part of Operation Warp Speed, a whole-of-America effort to rapidly develop, manufacture and distribute safe and effective COVID-19 vaccines to the American people. (DoD photo by Chief Mass Communication Specialist Charles Hayes)
May 10, 2021 - INO-4800 was shown to be safe, well-tolerated and immunogenic in all age groups. Phase 2 results informed INOVIO's selection of 2.0 mg dose for the Phase 3 segment of the trial...

Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing
April 26, 2021 - In July 2020, Immunome was awarded a $13.3 million agreement from the U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with...

SAB Biotherapeutics Doses First Patient with SAB-185 for the Treatment of COVID-19 in NIH’s ACTIV-2 Phase 2/3 Clinical Trial
Crystal Tyler, pharmacy technician, prepares an injection for an Operation Warp Speed patient volunteer at Brooke Army Medical Center, Fort Sam Houston, Texas, November 16, 2020. BAMC and Wilford Hall Ambulatory Surgical Center are participating in the Phase III trial to evaluate the vaccine under development by AstraZeneca as part of a national initiative to accelerate the development, production and distribution of COVID-19 vaccines, therapeutics and diagnostics. (U.S. Army photo by Jason W. Edwards)
April 21, 2021 - https://finance.yahoo.com/news/sab-biotherapeutics-doses-first-patient-200200245.html

Microbiologics Expands Virology Services to Support Drug and Vaccine Researchers and Developers
April 14, 2021 - Increases capabilities and capacity to provide anti-infective testing, assay development and biomaterial production services for highly infectious pathogens...

JPEO-CBRND Investment Initiates Phase II Clinical Trial Using Tafenoquine to Treat COVID-19
American Flags © iStock.com/ranckreporter
March 12, 2021 - FOR IMMEDIATE RELEASE - The JPM CBRN Medical executed an agreement with 60P to study the effectiveness of an existing drug that shows promise against COVID-19.FORT DETRICK, Md. – February 22, 2021 – The Department of Defense...

AstraZeneca to supply US with up to 500,000 additional doses of COVID-19 Long-Acting AntiBody combination AZD7442
March 12, 2021 - Agreement builds on an earlier announcement that included support for the clinical development and supply of the treatment...

Biden Administration secures supply of new COVID-19 therapeutic treatment
The South Carolina National Guard Medical Command receives its first shipment of COVID-19 Moderna vaccinations at McEntire Joint National Guard Base, South Carolina, Dec. 22, 2020. The South Carolina National Guard is a Moderna Department of Defense (DoD) vaccine pilot program state and is provided a limited DoD allocation for South Carolina National Guard Soldiers and Airmen to have the opportunity to voluntarily take the vaccine. The South Carolina National Guard remains ready to support the counties, local and state agencies and first responders with requested resources for as long as needed in support of COVID-19 response efforts in the state. (U.S. Air National Guard photo by Senior Master Sgt. Edward Snyder, South Carolina National Guard)
Feb. 26, 2021 - FOR IMMEDIATE RELEASE - The Biden Administration announced today that it has secured a supply of a recently authorized COVID-19 therapeutic treatment. The U.S. Department of Health and Human Services (HHS) and the Department...


Biden Administration purchases additional doses of COVID-19 vaccines from Pfizer and Moderna
The South Carolina National Guard Medical Command receives its first shipment of COVID-19 Moderna vaccinations at McEntire Joint National Guard Base, South Carolina, Dec. 22, 2020. The South Carolina National Guard is a Moderna Department of Defense (DoD) vaccine pilot program state and is provided a limited DoD allocation for South Carolina National Guard Soldiers and Airmen to have the opportunity to voluntarily take the vaccine. The South Carolina National Guard remains ready to support the counties, local and state agencies and first responders with requested resources for as long as needed in support of COVID-19 response efforts in the state. (U.S. Air National Guard photo by Senior Master Sgt. Edward Snyder, South Carolina National Guard)
Feb. 12, 2021 - FOR IMMEDIATE RELEASE - The U.S. Department of Health and Human Services (HHS) and Department of Defense (DOD) have purchased an additional 100 million doses of COVID-19 vaccines from both Pfizer Inc. and Moderna Inc. to help...

SAB Biotherapeutics Awarded $57.5M from BARDA and U.S. Department of Defense for Manufacturing of SAB-185 for the Treatment of COVID-19
Nov. 30, 2020 - SIOUX FALLS, S.D.--SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high-potency, fully human polyclonal antibodies without the...

DOD OTA Agreement Leveraged by Interagency for COVID-19 Rapid Response
April 10, 2020 - ABERDEEN PROVING GROUND, EDGEWOOD AREA, MD. – A Department of Defense (DOD) team led by the U.S. Air Force Agile Combat Support Program Executive Office Directorate (PEO ACS) leveraged an existing Other Transaction Authority...

DOD-Funded Diagnostic Test for COVID-19 Granted Emergency Use Authorization
March 31, 2020 - JPEO-CBRND’s industry partner BioFire Defense, LLC is producing COVID-19 tests to aid in pandemic response...

Ology Bioservices, Inovio Partner To Manufacture COVID-19 DNA Vaccine With $11.9 Million Department of Defense Grant
March 24, 2020 - ALACHUA, Fla. & PLYMOUTH MEETING, Pa.--March 24, 2020--Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), and Inovio Pharmaceuticals Inc., (NASDAQ: INO) developing DNA medicines...

Ology Bioservices, Vanderbilt University Medical Center to Develop, Manufacture Monoclonal Antibody for Treatment, Prevention of Infection With COVID-19 Virus for Department of Defense
March 23, 2020 - ALACHUA, Fla. – March 23, 2020 – The Department of Defense (DOD) awarded a contract valued at $14 million with Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), to develop and...

DOD Leveraging Diagnostic Platform for COVID-19 Rapid Response
March 11, 2020 - JPEO-CBRND’s JPM CBRN Medical facilitated use of existing contract capabilities to address the global coronavirus threat...